Azam Majidi1, Reza Ghiasvand1,2, Maryam Hadji1, Azin Nahvijou1, Azam-Sadat Mousavi3, Minoo Pakgohar4, Nahid Khodakarami5, Mehrandokht Abedini6, Farnaz Amouzegar Hashemi7, Marjan Rahnamaye Farzami8, Reza Shahsiah9, Sima Sajedinejhad10, Mohammad Ali Mohagheghi1, Fatemeh Nadali11, Arash Rashidian12, Elisabete Weiderpass13,14,15,16, Ole Mogensen17, Kazem Zendehdel1,18. 1. Cancer Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran. 2. Oslo Centre for Biostatistics and Epidemiology, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway. 3. Department of Genecology Oncology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. 4. Department of Reproductive Health, School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran. 5. Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 6. Deputy of Public Health, Maternal Office, Ministry of Health and Medical Education, Tehran, Iran. 7. Radiotherapy Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran. 8. Central Reference Laboratory, Ministry of Health and Medical Education, Tehran, Iran. 9. Department of Pathology, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran. 10. Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. 11. Faculty of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran. 12. Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. 13. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. 14. Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway. 15. Department of Research, Cancer Registry of Norway, Institute of Population-Based Cancer Research, Oslo, Norway. 16. Department of Genetic Epidemiology, Folkhälsan Research Center, Helsinki, Finland. 17. Department of Gynecology and Obstetrics, Odense University Hospital, Odense, Denmark. 18. Cancer Model Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran.
Abstract
BACKGROUND: Cervical cancer is the fourth most common cancer among women worldwide. Organized cervical screening and vaccination against human papilloma virus (HPV) have been successful interventions for prevention of invasive cervical cancer (ICC). Because of cultural and religious considerations, ICC has low incidence in Iran and many other Muslim countries. There is no organized cervical screening in these countries. Therefore, ICC is usually diagnosed in advanced stages with poor prognosis in these countries. We performed a priority setting exercise and suggested priorities for prevention of ICC in this setting. METHODS: We invited experts and researchers to a workshop and asked them to list important suggestions for ICC prevention in Iran. After merging similar items and removing the duplicates, we asked the experts to rank the list of suggested items. We used a strategy grid and Go-zone analysis to determine final list of priorities for ICC prevention in Iran. RESULTS: From 26 final items suggested as priorities for prevention of ICC, the most important priorities were developing national guidelines for cervical screening and quality control protocol for patient follow-up and management of precancerous lesions. In addition, we emphasized considering insurance coverage for cervical screening, public awareness, and research priorities, and establishment of a cervical screening registry. CONCLUSION: A comprehensive approach and implementation of organized cervical screening program is necessary for prevention of ICC in Iran and other low incidence Muslim countries. Because of high cost for vaccination and low incidence of cervical cancer, we do not recommend HPV vaccination for the time being in Iran.
BACKGROUND: Cervical cancer is the fourth most common cancer among women worldwide. Organized cervical screening and vaccination against human papilloma virus (HPV) have been successful interventions for prevention of invasive cervical cancer (ICC). Because of cultural and religious considerations, ICC has low incidence in Iran and many other Muslim countries. There is no organized cervical screening in these countries. Therefore, ICC is usually diagnosed in advanced stages with poor prognosis in these countries. We performed a priority setting exercise and suggested priorities for prevention of ICC in this setting. METHODS: We invited experts and researchers to a workshop and asked them to list important suggestions for ICC prevention in Iran. After merging similar items and removing the duplicates, we asked the experts to rank the list of suggested items. We used a strategy grid and Go-zone analysis to determine final list of priorities for ICC prevention in Iran. RESULTS: From 26 final items suggested as priorities for prevention of ICC, the most important priorities were developing national guidelines for cervical screening and quality control protocol for patient follow-up and management of precancerous lesions. In addition, we emphasized considering insurance coverage for cervical screening, public awareness, and research priorities, and establishment of a cervical screening registry. CONCLUSION: A comprehensive approach and implementation of organized cervical screening program is necessary for prevention of ICC in Iran and other low incidence Muslim countries. Because of high cost for vaccination and low incidence of cervical cancer, we do not recommend HPV vaccination for the time being in Iran.
Authors: Jill Barnholtz-Sloan; Nitin Patel; Dana Rollison; Karl Kortepeter; Jill MacKinnon; Anna Giuliano Journal: Cancer Causes Control Date: 2009-03-01 Impact factor: 2.506
Authors: J M Walboomers; M V Jacobs; M M Manos; F X Bosch; J A Kummer; K V Shah; P J Snijders; J Peto; C J Meijer; N Muñoz Journal: J Pathol Date: 1999-09 Impact factor: 7.996
Authors: Israel De Alba; F Allan Hubbell; Juliet M McMullin; Jamie M Sweningson; Richard Saitz Journal: J Gen Intern Med Date: 2005-03 Impact factor: 5.128
Authors: Christine M Pierce Campbell; Lynette J Menezes; Electra D Paskett; Anna R Giuliano Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-05-03 Impact factor: 4.254
Authors: Yasmin Bhurgri; Kauser Nazir; Yasmeen Shaheen; Ahmed Usman; Naveen Faridi; Hadi Bhurgri; Jawaid Malik; Imtiaz Bashir; Asif Bhurgri; Naila Kayani; Shahid Pervez; Sheema H Hasan; Faridoon Setna; S M H Zaidi Journal: Asian Pac J Cancer Prev Date: 2007 Jul-Sep
Authors: Iain Chalmers; Michael B Bracken; Ben Djulbegovic; Silvio Garattini; Jonathan Grant; A Metin Gülmezoglu; David W Howells; John P A Ioannidis; Sandy Oliver Journal: Lancet Date: 2014-01-08 Impact factor: 79.321
Authors: Rahim Taghizadeh Asl; Liesbeth Van Osch; Nanne De Vries; Kazem Zendehdel; Mohsen Shams; Fatemeh Zarei; Hein De Vries Journal: BMC Public Health Date: 2020-11-11 Impact factor: 3.295